Additional Paid-In Capital

9 Months Ended

Sep. 30, 2020

Additional Paid in Capital [Abstract]

Additional Paid-In Capital [Text Block]

11.	Additional Paid-In Capital
	Public Offering
	On February 11, 2020, IntelGenx announced the closing of 16,317,000 units (the "Units") at a price of CAD$0.50 ($0.37) for gross proceeds of CAD$8,158,500 ($6,116,000).
	Each Unit consists of one share of common stock of the Company and one warrant entitling the holder to purchase one share of common stock of the Company at an exercise price of CAD$0.75 ($0.56) per share. The Warrants are exercisable immediately and will expire on the third anniversary of the date of their issuance. Management has determined the value attributed to common stock is $3,912 thousand and $1,207 thousand for the warrants issued, resulting in an increase in additional paid-in-capital of $5,119 thousand.
	In connection with the Offering, the Company paid to the Agents a cash commission of approximately CAD$763,000 ($572,000) in the aggregate and issued non-transferable agents' warrants to the Agents, entitling the Agents to purchase 1,142,190 common shares at a price of CAD$0.75 ($0.56) per share until February 11, 2023. Management has determined the value of the agents' warrants to be $125,000, resulting in an increase in additional paid-in-capital of $125,000.
	The proceeds of the Units are attributed to equity components based on the fair value of each component as follows:

		Gross proceeds		Transaction costs		Net proceeds
Common stock	$	4,690	$	778	$	3,912
Warrants		1,447		240		1,207
	$	6,137	$	1,018	$	5,119

Stock options      

No options were granted during the nine-month period ended September 30, 2020.

In August 2020, the Board of directors amended the expiration time of 600,000 stock options granted to the President and CFO under the 2006 Stock Option Plan on July 20, 2020. The new expiration date is July 19, 2025, the original exercise price of $0.58 and all other terms remain unchanged. This extension resulted in the recognition of additional stock-based compensation expense of $31 thousand during the nine-month period ended September 30, 2020.

No stock options were exercised during the nine-month period ended September 30, 2020.

On March 27, 2019, 100,000 options to purchase common stock were granted to an employee under the 2016 Stock Option Plan. The options have an exercise price of $0.69. The options granted vest over a period of 2 years at a rate of 25% every six months and expire 10 years after the grant date. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $40 thousand.

During the nine-month period ended September 30, 2019 a total of 50,000 stock options were exercised for 50,000 common shares having a par value of $0 thousand in aggregate, for cash consideration of $21 thousand, resulting in an increase in additional paid-in capital of $21 thousand.

Compensation expenses for stock-based compensation of $172 thousand and $261 thousand were recorded during the nine-month periods ended September 30, 2020 and 2019, respectively. An amount of $140 thousand expensed in the nine-month period ended September 30, 2020 relates to stock options granted to employees and an amount of $32 thousand relates to stock options granted to consultants. An amount of $225 thousand expensed in the nine-month period ended September 30, 2019 relates to stock options granted to employees and directors and an amount of $36 thousand relates to stock options granted to a consultant. As at September 30, 2020, the Company has $17 thousand (2019 - $157 thousand) of unrecognized stock-based compensation.

Warrants

No warrants were exercised during the nine-month periods ended September 30, 2020 and 2019.

Deferred Share Units (“DSUs”)

On March 27, 2019, 271,740 DSUs have been granted under the DSU Plan.

No DSUs were granted in 2020.

Performance and Restricted Share Units (“PRSUs”)

No PRSUs were granted during the nine-month periods ended September 30, 2020 and 2019.